Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron C Burns

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The Journal of Organic Chemistry|May 24, 2018
Solvent-Controlled, Site-Selective N-Alkylation Reactions of Azolo-Fused Ring Heterocycles at N1-, N2-, and N3-Positions, Including Pyrazolo[3,4- d]pyrimidines, Purines, [1,2,3]Triazolo[4,5]pyridines, and Related Deaza-CompoundsBrett C Bookser, Michael I Weinhouse, Aaron C Burns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung CancerJoshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, et al.
Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant ProteinJohn M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Journal of Organic Chemistry|May 24, 2018
Solvent-Controlled, Site-Selective N-Alkylation Reactions of Azolo-Fused Ring Heterocycles at N1-, N2-, and N3-Positions, Including Pyrazolo[3,4- d]pyrimidines, Purines, [1,2,3]Triazolo[4,5]pyridines, and Related Deaza-CompoundsBrett C Bookser, Michael I Weinhouse, Aaron C Burns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2022
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung CancerJoshua K Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, et al.
Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant ProteinJohn M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
Pageof 2